Clinical Trial Update: A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated the combination of the MALT1 inhibitor JNJ-67856633 with Ibrutinib in patients with chronic lymphocytic leukemia and non-Hodgkin lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• JNJ-67856633

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED